Articles from argenx SE

argenx Highlights 2025 Strategic Priorities

By argenx SE · Via GlobeNewswire · January 13, 2025

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

By argenx SE · Via GlobeNewswire · January 6, 2025

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

By argenx SE · Via GlobeNewswire · December 27, 2024

argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.

By argenx SE · Via GlobeNewswire · November 26, 2024

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

By argenx SE · Via GlobeNewswire · November 20, 2024

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

By argenx SE · Via GlobeNewswire · November 11, 2024

argenx to Participate at Upcoming Investor Conferences

By argenx SE · Via GlobeNewswire · November 5, 2024

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

By argenx SE · Via GlobeNewswire · October 31, 2024

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

By argenx SE · Via GlobeNewswire · October 24, 2024

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

By argenx SE · Via GlobeNewswire · October 15, 2024

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

By argenx SE · Via GlobeNewswire · September 19, 2024

argenx to Present at Upcoming Investor Conferences

By argenx SE · Via GlobeNewswire · August 28, 2024

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

By argenx SE · Via GlobeNewswire · July 25, 2024

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

By argenx SE · Via GlobeNewswire · July 18, 2024

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

By argenx SE · Via GlobeNewswire · July 16, 2024

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

By argenx SE · Via GlobeNewswire · June 25, 2024

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

By argenx SE · Via GlobeNewswire · June 21, 2024

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

By argenx SE · Via GlobeNewswire · June 17, 2024

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

By argenx SE · Via GlobeNewswire · June 4, 2024

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

By argenx SE · Via GlobeNewswire · May 9, 2024

argenx announces results of Annual General Meeting of Shareholders

By argenx SE · Via GlobeNewswire · May 7, 2024

argenx to Present at BofA Securities 2024 Health Care Conference

By argenx SE · Via GlobeNewswire · May 7, 2024

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

By argenx SE · Via GlobeNewswire · May 2, 2024

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

By argenx SE · Via GlobeNewswire · April 16, 2024

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

By argenx SE · Via GlobeNewswire · March 27, 2024

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

By argenx SE · Via GlobeNewswire · March 26, 2024

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

By argenx SE · Via GlobeNewswire · March 26, 2024

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

By argenx SE · Via GlobeNewswire · March 7, 2024

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

By argenx SE · Via GlobeNewswire · February 29, 2024

argenx to Present at Upcoming Investor Conferences

By argenx SE · Via GlobeNewswire · February 26, 2024

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

By argenx SE · Via GlobeNewswire · February 22, 2024

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

By argenx SE · Via GlobeNewswire · February 20, 2024

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

By argenx SE · Via GlobeNewswire · January 18, 2024

argenx Highlights 2024 Strategic Priorities

By argenx SE · Via GlobeNewswire · January 8, 2024

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

By argenx SE · Via GlobeNewswire · January 2, 2024

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

By argenx SE · Via GlobeNewswire · December 20, 2023

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

By argenx SE · Via GlobeNewswire · November 28, 2023

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe

By argenx SE · Via GlobeNewswire · November 16, 2023

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

By argenx SE · Via GlobeNewswire · November 1, 2023

argenx to Present at Upcoming Investor Conferences

By argenx SE · Via GlobeNewswire · November 1, 2023

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

By argenx SE · Via GlobeNewswire · October 31, 2023

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

By argenx SE · Via GlobeNewswire · October 24, 2023

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

By argenx SE · Via GlobeNewswire · September 21, 2023

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

By argenx SE · Via GlobeNewswire · September 15, 2023

argenx to Present at Upcoming Investor Conferences

By argenx SE · Via GlobeNewswire · August 30, 2023

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

By argenx SE · Via GlobeNewswire · July 27, 2023

argenx announces closing of global offering

Regulated information – Inside information

By argenx SE · Via GlobeNewswire · July 24, 2023

argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

By argenx SE · Via GlobeNewswire · July 20, 2023

argenx announces full exercise of underwriters’ option to purchase additional ADSs

Regulated information — Inside information

By argenx SE · Via GlobeNewswire · July 19, 2023

argenx raises $1.1 billion in gross proceeds in a global offering

Regulated information — Inside information

By argenx SE · Via GlobeNewswire · July 18, 2023

argenx announces launch of proposed global offering

Regulated information — Inside information

By argenx SE · Via GlobeNewswire · July 17, 2023

argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

By argenx SE · Via GlobeNewswire · July 17, 2023

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

By argenx SE · Via GlobeNewswire · June 30, 2023

argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis

By argenx SE · Via GlobeNewswire · June 20, 2023

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

By argenx SE · Via GlobeNewswire · June 20, 2023

argenx to Present at Upcoming Investor Conferences

By argenx SE · Via GlobeNewswire · May 31, 2023

argenx Reports First Quarter 2023 Financial Results and Provides Business Update

By argenx SE · Via GlobeNewswire · May 4, 2023

argenx announces results of Annual General Meeting of Shareholders

By argenx SE · Via GlobeNewswire · May 3, 2023

argenx to Present at BofA Securities 2023 Health Care Conference

By argenx SE · Via GlobeNewswire · May 2, 2023

argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023

By argenx SE · Via GlobeNewswire · April 27, 2023

argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting

By argenx SE · Via GlobeNewswire · April 18, 2023

argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

By argenx SE · Via GlobeNewswire · April 17, 2023

argenx Announces Annual General Meeting of Shareholders on May 2, 2023

By argenx SE · Via GlobeNewswire · March 17, 2023

argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis

By argenx SE · Via GlobeNewswire · March 15, 2023

argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update

By argenx SE · Via GlobeNewswire · March 2, 2023

argenx Announces Planned Transition of Chief Operating Officer

By argenx SE · Via GlobeNewswire · March 2, 2023

argenx Appoints Steve Krognes to Board of Directors

By argenx SE · Via GlobeNewswire · February 27, 2023

argenx to Present at Upcoming Investor Conferences

By argenx SE · Via GlobeNewswire · February 27, 2023

argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023

By argenx SE · Via GlobeNewswire · February 23, 2023

argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod

January 27, 2023

By argenx SE · Via GlobeNewswire · January 27, 2023

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

January 16, 2023

By argenx SE · Via GlobeNewswire · January 16, 2023

argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline

Reported $402 million in preliminary* full-year 2022 global net VYVGART sales

By argenx SE · Via GlobeNewswire · January 9, 2023

argenx to Present at 41st Annual J.P. Morgan Healthcare Conference

By argenx SE · Via GlobeNewswire · January 3, 2023

argenx Appoints Ana Cespedes to Board of Directors

By argenx SE · Via GlobeNewswire · December 12, 2022

argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia

First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease

By argenx SE · Via GlobeNewswire · December 10, 2022